이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Ind-Swift 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Gopal Munjal

최고 경영자

₹18.0m

총 보상

CEO 급여 비율	100.0%
CEO 임기	16.3yrs
CEO 소유권	3.6%
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	16yrs

최근 관리 업데이트

Recent updates

CEO 보상 분석

Gopal Munjal 의 보수는 Ind-Swift 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	₹142m
Dec 31 2023	n/a	n/a	₹298m
Sep 30 2023	n/a	n/a	₹437m
Jun 30 2023	n/a	n/a	₹438m
Mar 31 2023	₹18m	₹18m	₹260m
Dec 31 2022	n/a	n/a	-₹318m
Sep 30 2022	n/a	n/a	-₹375m
Jun 30 2022	n/a	n/a	-₹319m
Mar 31 2022	₹18m	₹18m	-₹200m
Dec 31 2021	n/a	n/a	-₹320m
Sep 30 2021	n/a	n/a	-₹272m
Jun 30 2021	n/a	n/a	-₹245m
Mar 31 2021	₹15m	₹15m	-₹298m
Dec 31 2020	n/a	n/a	-₹171m
Sep 30 2020	n/a	n/a	-₹277m
Jun 30 2020	n/a	n/a	-₹254m
Mar 31 2020	₹12m	₹12m	-₹191m
Dec 31 2019	n/a	n/a	-₹4m
Jun 30 2019	n/a	n/a	₹48m
Mar 31 2019	₹12m	₹12m	₹82m
Mar 31 2018	₹12m	₹12m	-₹504m

보상 대 시장: Gopal 의 총 보상 ($USD 215.57K )은 Indian 시장( $USD 38.49K ).

보상과 수익: Gopal 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Gopal Munjal (66 yo)

16.3yrs

테뉴어

₹18,000,000

보상

Dr. Gopal Munjal, M.D. has been the Chief Executive Officer and Managing Director of Ind-Swift Ltd. since April 2008. Dr. Munjal has experience in Pharmaceutical industry.Dr. Munjal served as the Chairman...

이사회 구성원

이름	위치	테뉴어	보상	소유권
Sanjeev Mehta	Executive Chairman	17.7yrs	₹18.00m	3.76% ₹ 42.9m
Gopal Munjal	CEO, MD & Whole Time Director	37.6yrs	₹18.00m	3.61% ₹ 41.2m
Vikrant Mehta	Joint MD & Whole Time Director	30.8yrs	₹18.00m	3.55% ₹ 40.4m
Navrattan Munjal	Non-Executive Director	37.6yrs	₹65.00k	1.37% ₹ 15.6m
Himanshu Jain	Non-Executive Director	20.9yrs	₹85.00k	0.91% ₹ 10.4m
Rishav Mehta	Non-Executive Director	14.3yrs	₹45.00k	0.21% ₹ 2.4m
Subhash Galhotra	Independent Director	7.6yrs	₹70.00k	데이터 없음
Anoop Michra	Independent Woman Director	7.2yrs	₹55.00k	데이터 없음
Jagvir Ahluwalia	Non-Executive Independent Director	6.9yrs	₹70.00k	데이터 없음
Bhupinder Singh	Non-Executive Independent Director	2.1yrs	₹55.00k	데이터 없음

16.0yrs

평균 재임 기간

66yo

평균 연령

경험이 풍부한 이사회: 524652 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 15.9 년).

Ind-Swift 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Ind-Swift Limited Announces Cessation of Vinay Arora as an Independent Director

Ind-Swift Limited, Annual General Meeting, Sep 30, 2023

Insufficient new directors

Ind-Swift Approves Appointment of Sh. Bhupinder Singh as an Independent Director

Ind-Swift Limited, Annual General Meeting, Sep 21, 2022

Ind-Swift Limited Appoints Ginny Uppal as Company Secretary and Compliance Officer

Recent updates

New minor risk - Earnings quality

Full year 2024 earnings released: EPS: ₹2.63 (vs ₹4.81 in FY 2023)

Ind-Swift Limited to Report Q4, 2024 Results on May 14, 2024

Investor sentiment deteriorates as stock falls 16%

Investor sentiment improves as stock rises 29%

Investor sentiment improves as stock rises 21%

Ind-Swift Limited Announces Cessation of Vinay Arora as an Independent Director

Investor sentiment improves as stock rises 16%

Third quarter 2024 earnings released: ₹2.76 loss per share (vs ₹0.19 loss in 3Q 2023)

Investor sentiment improves as stock rises 18%

Ind-Swift Limited to Report Q3, 2024 Results on Feb 13, 2024

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 16%

Second quarter 2024 earnings released: ₹1.98 loss per share (vs ₹1.96 loss in 2Q 2023)

Ind-Swift Limited to Report Q2, 2024 Results on Nov 09, 2023

New major risk - Market cap size

Investor sentiment deteriorates as stock falls 16%

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Laboratories Limited (NSEI:INDSWFTLAB) agreed to acquire Ind-Swift Limited (BSE:524652).

Ind-Swift Limited, Annual General Meeting, Sep 30, 2023

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 21%

First quarter 2024 earnings released: EPS: ₹0.44 (vs ₹2.85 loss in 1Q 2023)

Ind-Swift Limited to Report Q1, 2024 Results on Aug 10, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 18%

Full year 2023 earnings released: EPS: ₹4.81 (vs ₹3.70 loss in FY 2022)

Ind-Swift Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released

Ind-Swift Limited to Report Q3, 2023 Results on Feb 13, 2023

Second quarter 2023 earnings released: ₹1.96 loss per share (vs ₹0.91 loss in 2Q 2022)

Insufficient new directors

Ind-Swift Limited to Report Q2, 2023 Results on Nov 14, 2022

Ind-Swift Approves Appointment of Sh. Bhupinder Singh as an Independent Director

First quarter 2023 earnings released: ₹2.85 loss per share (vs ₹0.66 loss in 1Q 2022)

Ind-Swift Limited, Annual General Meeting, Sep 21, 2022

Ind-Swift Limited to Report Q1, 2023 Results on Aug 09, 2022

Full year 2022 earnings released: ₹3.70 loss per share (vs ₹5.51 loss in FY 2021)

Ind-Swift Limited Appoints Ginny Uppal as Company Secretary and Compliance Officer

Ind-Swift Limited to Report Q4, 2022 Results on May 30, 2022

Less than half of directors are independent

Ind-Swift Limited Announces the Resignation of Amrender Kumar Yadav as Company Secretary & Compliance Officer

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Ind-Swift Limited to Report Q3, 2022 Results on Feb 14, 2022

First quarter 2022 earnings released: ₹0.66 loss per share (vs ₹1.64 loss in 1Q 2021)

ANG Lifesciences India Limited (BSE:540694) acquired Two Formulation Manufacturing Facilities from Ind-Swift Limited (BSE:524652) for INR 600 million.

Full year 2021 earnings released: ₹5.50 loss per share (vs ₹3.53 loss in FY 2020)

Third quarter 2021 earnings released: ₹0.22 loss per share (vs ₹2.18 loss in 3Q 2020)

Ind-Swift Limited to Report Q3, 2021 Results on Feb 13, 2021

New 90-day low: ₹3.01

Second quarter 2021 earnings released: ₹0.42 loss per share

New 90-day high: ₹3.59

New 90-day high - ₹3.50

Earnings released

CEO 보상 분석

CEO

테뉴어

보상

이사회 구성원

평균 재임 기간

평균 연령